Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

. Author manuscript; available in PMC: 2014 Oct 15.

Published in final edited form as: Stroke. 2008 Mar 5;39(5):1647–1652. doi: 10.1161/STROKEAHA.107.189063

Writing Group Member	Employment	Research Grant	Speakers’ Bureau/Honoraria	Stock Ownership	Consultant/Advisory Board	Other
Robert J. Adams	Medical University of South Carolina	None	Bristol-Myers Squib^; Boehringer Ingelheim^†; Novartis^; Sanofi-Synthelabo^*	None	Bristol-Myers Squib^; Boehringer Ingelheim^; Sanofi-Synthelabo^*	Nicolet^*
Greg Albers	Stanford University	National Institutes of Health^†; Aventis^†; AstraZeneca^†; Genentech^†; Pfizer^†; Boehringer Ingelheim^†; Novartis^†; Paion/Forest^†; National Stroke Association^†	Genetech^; Boehringer Ingelheim^	None	Boehringer Ingelheim^; General Electric^; Sanofi/Aventis^*	None
Mark J. Alberts	Northwestern University Medical School	AGA Medical^; Boehringer Ingelheim^; Bristol-Myers Squib^†; Sanofi/Synthelabo^†; Schering-Plough^*	Accumetrics^; AstraZeneca^; Boehringer Ingelheim^; Bristol-Myers Squib^†; diaDexus^; Pfizer^*; Sanofi/Synthelabo^†	None	Accumetrics^; AstraZeneca^; Bayer^; Boehringer Ingelheim^; Bristol-Myers Squib^†; diaDexus^; Pfizer^; Sanofi/Synthelabo^†; Schering-Plough^*	Athena^; Mitsubishi^; TAP Pharmaceuticals^*
Oscar Benavente	University of Texas Health Science Center	Bristol-Myers Squib^†; Sanofi/Synthelabo^†	Bristol-Myers Squib^; Sanofi/Synthelabo^	None	Bristol-Myers Squib^; Sanofi/Synthelabo^; Pfizer^*	None
Karen Furie	Massachusetts General Hospital	None	None	None	GE Health^; Pfizer Pharmaceutical^	None
Larry B. Goldstein	Duke University Medical Center and Durham VA Medical Center	AGA Medical^†; Boehringer Ingelheim^*	Pfizer^†	None	Daiichi^; Pfizer^†; Sankyo^; TAP Pharmaceuticals^*	None: He excused himself from any discussions or recommendations on statins/SPARCL.
Philip Gorelick	University of Illinois at Chicago	None	Boehringer Ingelheim^†	None	Pfizer^; Novartis^; diaDexus^*; Bayer^†; Boehringer Ingelheim^†	None
Jonathan Halperin	Mount Sinai Medical Center	None	None	None	Astellas Pharma^; Bayer HealthCare^; Biotronik^†; Boehringer Ingelheim^; Daiichi-Sankyo Pharma^; Johnson & Johnson^; Sanofi-Aventis^	None
Robert Harbaugh	Pennsylvania State University, Milton S. Hershey Medical Center	Codman, Inc^†; Medtronic, Inc^†; Integra Neuroscience, Inc^†; Integra Foundation^†; Wyoming Valley Healthcare System^†; Commonwealth of Pennsylvania^†	None	Cortex, Inc^†; MedCool, Inc^†; Piezo Resonance Innovations, Inc.^†	MedCool, Inc.^†; Micromechatronics, Inc^†; Piezo Resonance Innovations, Inc^†; SIO Healthcare Advisors^†	CHYNA, LLC–President^†; US Patent Applications 20070138915 and 20060212097
S. Claiborne Johnston	University of California San Francisco Medical Center/Department of Neurology	Boston Scientific^†; Brainsgate^; NTI^; Sanofi-Aventis^†	None	None	Daiichi-Sankyo^*	National Stroke Association^*
Irene Katzan	MetroHealth Medical Center and Cleveland Clinic Foundation	None	Genentech^*	None	None	Novartis^†
Margaret Kelly-Hayes	Boston University	None	None	None	None	None
Edgar J. Kenton	Jefferson Health System Wynnewood	None	None	None	None	None
Michael Marks	Stanford University	None	None	Chestnut Medical^*	Chestnut Medical^; Ev3^; Micrus^*
Ralph L. Sacco	University of Miami	None	Boehringer Ingelheim^*	None	Boehringer Ingelheim^†; GlaxoSmithKline^*	None
Lee H. Schwamm	Massachusetts General Hospital and Massachusetts Institute of Technology	None	None	None	CoAxia, Inc^†; Phreesia^; Cryocath^	RTI^*; MA DPH^†

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12 month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

Modest.

^†

Significant.